Navigation Links
Former Telomolecular CEO Clarifies SEC Settlement
Date:11/3/2008

Former Telomolecular CEO, Matthew Sarad, clarifies the scope and terms of his settlement with the SEC. Case No. 2:08-cv-2252-GEB-DAD.

(PRWEB) November 3, 2008 -- Telomolecular, a Rancho Cordova, California Corporation, was formed in 2005 to develop and license new nanotechnology based therapeutics to treat diseases of aging and cancer, particularly diseases related to chromosomal telomere shortening. The Company worked with a number of known U.S. universities and hospitals including but not limited to Stanford, the University of Nebraska, and the third largest hospital in the country, the Cleveland Clinic, where Telomolecular's anticancer therapeutics are being presently studied in living animals. The SEC alleged in a complaint (Case No. 2:08-cv-2252-GEB-DAD) filed in a Sacramento, California court in September of 2008, that the Corporation's Chief Executive Officer, Mr. Matthew Sarad, misrepresented key facts to investors related to the number and involvement level of certain employees, the corporation's progress towards an IPO, and two material financial transactions. Without admitting or denying the charges Mr. Sarad reached a settlement that required that he pay a $100,000 fine and not serve as an officer or director of a publicly traded U.S. company for a period of five years.

According to Mr. Sarad, "I had no practical way to litigate the government and just wanted to put this unfortunate episode of my career behind me. Resigning from Telomolecular was truly heartbreaking for me given the many years of very hard work. We were all working in the interests of our investors and in the interests of science. The number of extraordinary assets and opportunities the company possesses is impressive and I believe the new CEO will break into global pharmaceutical markets with our cutting edge goods. Telomolecular was, and is one of the most important and most promising technology companies i
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

2

GOOD

Page: 1 2 3

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
4. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
7. Former Patent Office Solicitor and Judge Joins Rothwell Figg
8. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
9. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
10. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
11. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2009)...alysis technique that identifies and removes syste...om experimental data could lead to more precise an...ructures likely to have future industrial applicat...y regression (SPAR), the technique could also redu...e conclusions, and help distinguish true nanoscale...
(Date:7/1/2009)...wswire/ -- Johnson & Johnson today announc...tment of Molecular Biology at the Max Planck Insti... have led to novel cancer therapies including Herc... Dr. Paul Janssen Award for Biomedical Research. A...ts selected Dr. Ullrich, who on September 8 will r...
(Date:7/1/2009)... stimulant to establish duration of efficacy from ...dults with ADHD , , HOLLYWOOD, Fla., July 1 /PR...: SHPGY ), the global specialty biopharmaceutica... study that found VYVANSE(R) (lisdexamfetamine dim...14 hours after administration during a simulated w...
(Date:7/1/2009)...Newswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: ...al gross funds of over $4 million from institution...th the $11 million private placement from three As... the total investment obtained by NeoStem in the p...ddition, affiliates of Suzhou Erye Pharmaceuticals...
Breaking Biology Technology:New statistical technique improves precision of nanotechnology data 2New statistical technique improves precision of nanotechnology data 3New statistical technique improves precision of nanotechnology data 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 3Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 2Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 3Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 4Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 6Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 7Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 8NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State 2NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State 3
...ison, Wis. OpGen , a company that makes optical...ces between individuals, has completed the final s... a two-year-old company based on University of Wis...ng services to a variety of clients. The latest in...ice and new developments such as packaged instrume...
...was going to write todays column about a toilet se...ntroversy swirled around the fact that Iand 99 oth... ,Last fall I was asked to become part of the Sili... extraordinaire and Stonebrick Group founder Auren...rtue of their work or their own networking prowess...
...le names new secretary of commerce ,Wisconsin Gov...most recently the director of forecasting and pla...commerce secretary starting February 7. Her predec...04 to take a job with a law firm. , Business-plan ...business-plan contest will stop accepting submissi...
...cluster of neural cells were derived from human em...e motor neurons are shown in red, neural fibers ap...ll nuclei. Photo courtesy of UW-Madison. Madison...onsin-Madison has succeeded in enticing human embr...he cells that transmit messages from the brain to ...
Other Biology Technology:OpGen completes $5 million investment round 2The myth of objectivity 2The myth of objectivity 3Science in motion 2Science in motion 3
(Date:7/2/2009)...merhaven, July 2nd 2009. A new measurement system ...time on board of the research vessel Polarstern. W...nd, they spend the greater part of their life unde...heir body can be seen when they surface, and this ...ing water. Visual sightings by marine mammal obser...
(Date:7/2/2009)...M, N.C. -- As flowering plants like giant trees qu...e Cretaceous period, the ferns that had preceded t..., they flourished. While modern tropical rain fore...d, and experienced a flowering of their own specie...-- diversification," said Duke University research...
(Date:7/1/2009)...n, 1 July, 2009 Johnson & Johnson today announced...ent of Molecular Biology at the Max Planck Institu...ave led to novel cancer therapies including Hercep...Paul Janssen Award for Biomedical Research. An in...elected Dr. Ullrich, who on September 8 will recei...
(Date:7/1/2009)...earchers from the Department of Science Education-...aged to make out the "self-irrigating" mechanism o...16 times the amount of water than otherwise expect...ies of rain in the desert. This is the first examp...esert rhubarb grows in the mountains of Israel,s N...
Breaking Biology News(10 mins):All in sight 2Ferns took to the trees and thrived 2Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Desert rhubarb -- a self-irrigating plant 2eRx Network 28R 29 Expands eRx CardFinder 28TM 29 Reach 37037 1eRx Network 28R 29 Expands eRx CardFinder 28TM 29 Reach 37037 2Blood Drive Held in Honor of Sewell NJ Resident Ellie Koerner 37033 1Blood Drive Held in Honor of Sewell NJ Resident Ellie Koerner 37033 2Blood pressure compound may benefit brain tumor patients 37029 1Blood pressure compound may benefit brain tumor patients 37029 2Blood pressure compound may benefit brain tumor patients 37029 3IOF joins ECCEO9 at leading international meeting in Athens 37025 1
...nign virus previously used as a marker in tracing ...searchers at Penn State. Results of this study als...ch higher rates of evolution than previously thoug...tions are in Africa," said Laura Shackelton, a pos...fectious Disease Dynamics. "But, in the case of th...
...ntists at Wake Forest University Baptist Medical C... have launched a $10 million multi-year study to i...clerosis. , "If we can identify people in their t...sposition to develop atherosclerosis, we can manag...sooner and more aggressively," said David Herringt...
... new twist on the slogan “milk does a body good,?r... a contrast agent in gastrointestinal imaging exam... their findings today at the annual meeting of the...We are able to achieve similar bowel distension an...trast agent, VoLumen,?said Lisa R. Shah-Patel, M....
...w technique devised by MIT engineers may one day h...y stages of growth. , The technique allows nanopar...creating masses with enough of a magnetic signal t...RI) machine. , The work appears as the cover feat...ional Edition, one of the world,s leading chemistr...
Other Biology News:Viral marker of human migration suspect 2Scientists work to identify genes that contribute to early heart attack risk 2Got inexpensive contrast agent? Milk plays new role in imaging 2MIT nanoparticles may help detect, treat tumors 2
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A
...cisION Ion Channel Cell Lines ,High Quality, Funct...hannels are well known for having a critical role ... a key function in pain, CNS and the heart. Drugs ...in therapeutic areas, such as neuropathic pain, ca...
Biology Products: